Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Immune checkpoint inhibitors (ICIs) have dramatically improved the outcomes of non-small cell lung cancer patients and have increased the possibility of long-term survival. However, few patients benefit from ICIs, and no predictive biomarkers other than tumor programmed cell death ligand 1 (PD-L1) e...

Descripción completa

Detalles Bibliográficos
Autores principales: Ushio, Ryota, Murakami, Shuji, Saito, Haruhiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000007/
https://www.ncbi.nlm.nih.gov/pubmed/35407463
http://dx.doi.org/10.3390/jcm11071855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000007/
https://www.ncbi.nlm.nih.gov/pubmed/35407463
http://dx.doi.org/10.3390/jcm11071855

Ejemplares similares